JP

Jason Parnes

SP Signal Pharmaceuticals: 18 patents #11 of 207Top 6%
📍 San Diego, CA: #2,391 of 23,606 inventorsTop 15%
🗺 California: #32,725 of 386,348 inventorsTop 9%
Overall (All Time): #252,592 of 4,157,543Top 7%
18
Patents All Time

Issued Patents All Time

Showing 1–18 of 18 patents

Patent #TitleCo-InventorsDate
11292796 Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors Jan Elsner, Roy L. Harris, Branden Lee, Deborah Mortensen, Garrick Packard +7 more 2022-04-05
10683298 Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors Jan Elsner, Roy L. Harris, Branden Lee, Deborah Mortensen, Garrick Packard +7 more 2020-06-16
10167290 Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors Jan Elsner, Roy L. Harris, Branden Lee, Deborah Mortensen, Garrick Packard +7 more 2019-01-01
9783505 Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith Patrick Papa, Brian E. Cathers, Andrew Antony Calabrese, Brandon W. Whitefield, Brydon L. Bennett +14 more 2017-10-10
9771371 Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors Jan Elsner, Roy L. Harris, Branden Lee, Deborah Mortensen, Garrick Packard +7 more 2017-09-26
9556126 Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith Patrick Papa, Brian E. Cathers, Andrew Antony Calabrese, Brandon W. Whitefield, Brydon L. Bennett +14 more 2017-01-31
9193692 Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa +6 more 2015-11-24
9156798 Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith Sogole Bahmanyar, Andrew Antony Calabrese, Daniel K. Cashion, Brian E. Cathers, Matthew D. Correa +13 more 2015-10-13
8907087 Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa +6 more 2014-12-09
8507492 Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa +12 more 2013-08-13
8492381 Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa +12 more 2013-07-23
8383634 Methods of treatment using heteroaryl compounds and compositions thereof Deborah Mortensen, Maria Mercedes Delgado Mederos, John Sapienza, Ronald Albers, Steven S. Clareen +5 more 2013-02-26
8372976 Methods of treatment comprising the administration of heteroaryl compounds Deborah Mortensen, Maria Mercedes Delgado Mederos, John Sapienza, Ronald Albers, Branden Lee +9 more 2013-02-12
8110578 Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa +12 more 2012-02-07
7981893 Heteroaryl compounds, compositions thereof, and methods of treatment therewith Deborah Mortensen, Maria Mercedes Delgado Mederos, John Sapienza, Ronald Albers, Branden Lee +9 more 2011-07-19
7968556 Heteroaryl compounds, compositions thereof, and methods of treatment therewith Deborah Mortensen, Maria Mercedes Delgado Mederos, John Sapienza, Ronald Albers, Steven S. Clareen +5 more 2011-06-28
7442699 Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto Adam Kois, Karen J. MacFarlane, Yoshitaka Satoh, Shripad S. Bhagwat, Moorthy S. S. Palanki +1 more 2008-10-28
7122544 Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto Adam Kois, Karen J. MacFarlane, Yoshitaka Satoh, Shripad S. Bhagwat, Moorthy S. S. Palanki +1 more 2006-10-17